Information Provided By: 
Fly News Breaks for September 21, 2016
PBYI
Sep 21, 2016 | 07:08 EDT
Stifel analyst Thomas Shrader upgraded Puma after it announced that the FDA had accepted for review the New Drug Application for neratinib in the extended adjuvant treatment. The analyst says that the news "is unusually important..due to procedural irregularities" in a trial. He adds that doctors are becoming more enthusiastic about the drug which meets a significant unmet need. He thinks that its safety issues "look to be under reasonable control," and he now thinks the drug has a 90% chance of being approved. Target to $88 from $61.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
